Intellia Therapeutics Inc Cash Flow-to-Debt Ratio
Intellia Therapeutics Inc cash flow-to-debt ratio. Intellia Therapeutics Inc (NTLA) has a Cash Flow-to-Debt Ratio of -0.41x as of December 2025, meaning its operating cash flow of $-69.28 Million could theoretically repay 0% of its total liabilities ($170.73 Million) in one year. See Intellia Therapeutics Inc financial flexibility index to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Intellia Therapeutics Inc (2014–2025)
Cash flow-to-debt ratio of Intellia Therapeutics Inc from 2014 to 2025. Historical debt coverage capacity for Intellia Therapeutics Inc across 12 annual periods. Check NTLA cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Intellia Therapeutics Inc Cash Flow-to-Debt Ratio by Year (2014–2025)
Intellia Therapeutics Inc cash flow-to-debt ratio by year from 2014 to 2025. Year-by-year debt coverage analysis for Intellia Therapeutics Inc. For the full cash flow conversion analysis, see NTLA cash generation efficiency.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -2.04x | $-348.88 Million | $170.73 Million | ▼ -86.9% |
| 2024 | -1.09x | $-348.88 Million | $319.06 Million | ▲ +30.4% |
| 2023 | -1.57x | $-394.09 Million | $250.81 Million | ▼ -34.1% |
| 2022 | -1.17x | $-333.29 Million | $284.53 Million | ▼ -32.3% |
| 2021 | -0.89x | $-225.03 Million | $254.22 Million | ▼ -164.7% |
| 2020 | -0.33x | $-49.91 Million | $149.25 Million | ▲ +79.1% |
| 2019 | -1.60x | $-103.24 Million | $64.40 Million | ▼ -81.6% |
| 2018 | -0.88x | $-61.26 Million | $69.39 Million | ▼ -2.3% |
| 2017 | -0.86x | $-65.28 Million | $75.64 Million | ▼ -313.0% |
| 2016 | 0.41x | $36.11 Million | $89.13 Million | ▲ +439.7% |
| 2015 | -0.12x | $-1.76 Million | $14.78 Million | ▲ +89.3% |
| 2014 | -1.11x | $-3.48 Million | $3.13 Million | — |